Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura

Table 3 Demographic and main treatment characteristics based on patient’s seroprotection status

	Seroprotection status		p-value
	Partially protected	Fully susceptible*	p-value
Sex
Male (n = 66)	46 (69.7%)	20 (30.3%)	0.513^a
Female (n = 44)	34 (77.3%)	10 (22.7%)
Age	5.32 (SE ± 0.31)	4.33 (SE ± 0.52)	0.060^b
Chemotherapy sessions (numbers)	13.10 (SE ± 1.18)	36.20 (SE ± 1.48)	< 0.001^b
Malignancy versus ITP
ITP	50 (100.0%)	0 (0.0%)	< 0.001^a
Malignancy	30 (50.0%)	30 (50.0%)

ISSN: 1471-2334